Portugal's Regulator Defends Cannabis Crackdown as Export Permits Stall

Enforcement Sweep Targets Compliance Gaps in Export Chain

INFARMED suspended export authorizations for at least three licensed cannabis producers in late August 2026, citing violations of Good Manufacturing Practice (GMP) standards and traceability failures. The regulator's September 14 statement described the enforcement actions as "necessary to preserve the integrity of Portugal's medical-cannabis framework." It didn't name the affected companies. It didn't specify which violations triggered each suspension.

The agency confirmed it opened formal administrative proceedings against two producers for potential license revocation. Those cases remain pending. INFARMED said it would release detailed findings only after the proceedings conclude—a timeline the agency didn't specify.

Portugal authorized medical-cannabis cultivation and export in 2018 under Law 33/2018. Since then, the country has issued approximately 40 cultivation licenses, making it one of Europe's largest legal-cannabis exporters by volume. Most output flows to Germany, the United Kingdom, and Switzerland.

Export Permits Frozen Since Late August

The enforcement actions have effectively frozen exports for the suspended operators since August 28, 2026, according to industry sources. INFARMED's export-authorization system requires active GMP certification and quarterly compliance audits. Suspended operators can't ship product until INFARMED reinstates their export permits, a process the agency said depends on "full remediation of identified deficiencies."

The regulator didn't provide a timeline for reinstatement reviews. One suspended operator, speaking on condition of anonymity, told CannIntel the company submitted a corrective-action plan on September 3 but has received no feedback from INFARMED as of September 13.

Portugal's cannabis-export volume reached approximately 12 metric tons in 2025, generating an estimated €85 million in declared export value, according to customs data. The three suspended operators collectively represent roughly 20 percent of Portugal's licensed cultivation capacity, based on publicly disclosed facility sizes.

Regulator Cites Traceability and GMP Violations

INFARMED's statement identified two primary violation categories: failures in seed-to-sale traceability systems and lapses in GMP environmental controls. Inspectors documented "incomplete batch records, inadequate environmental monitoring, and gaps in chain-of-custody documentation" during audits conducted between June and August 2026, the agency said.

The regulator didn't specify whether the violations involved diversion risk, contamination, or paperwork deficiencies. All findings are documented in confidential audit reports that will be disclosed only if enforcement proceedings result in license revocation, INFARMED said.

Portugal's GMP standards for cannabis align with European Medicines Agency (EMA) guidelines, which require validated environmental controls, batch-level traceability, and quarterly third-party audits. Operators must maintain GMP certification to hold an active export authorization.

Industry Groups Call for Transparency on Enforcement Criteria

Two Portuguese cannabis-industry associations requested that INFARMED publish anonymized summaries of the alleged violations to help operators understand enforcement thresholds. The Portuguese Medical Cannabis Association (APCM) and the Cannabis Industry Association of Portugal (ACIP) issued a joint statement September 12 asking for "clear, public guidance on the compliance standards that triggered these suspensions."

Confidential enforcement creates uncertainty for operators and investors, the groups argued. APCM's statement noted that "without transparency on what constitutes a material violation, producers can't calibrate their compliance programs effectively."

INFARMED hasn't responded to the associations' request. The regulator's September 14 statement said only that "enforcement decisions are based on documented evidence and follow established administrative procedures."

Export Market Impact and Operator Response

The suspensions have disrupted supply contracts with at least two German pharmaceutical distributors, according to trade sources. Germany imported approximately 4.2 metric tons of medical cannabis from Portugal in 2025, making it Portugal's largest export market. One German distributor confirmed to CannIntel that a scheduled September shipment from a Portuguese supplier was canceled due to "regulatory issues," but the distributor declined to name the supplier.

An estimated 1,200 workers are employed across Portugal's cannabis sector in cultivation, processing, and logistics. The suspended operators haven't announced layoffs, but one company told employees in an internal memo reviewed by CannIntel that it's "evaluating operational adjustments" while the export freeze remains in effect.

For full background on Portugal's medical-cannabis framework and licensing history, see the CannIntel topic hub on Portugal Cannabis Regulation.

The next signal: INFARMED's quarterly compliance report, typically published in late October, may provide aggregated data on inspection outcomes and enforcement trends. Operators are watching whether the agency will issue updated GMP guidance or clarify traceability requirements before the end of 2026.